Published in Nature on January 03, 2001
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol (2009) 4.52
Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A (2006) 3.70
Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov (2010) 3.48
Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci (2008) 3.25
Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci (2010) 2.99
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain (2011) 2.76
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov (2010) 2.58
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A (2001) 2.53
Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci U S A (2006) 2.45
Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci U S A (2012) 2.36
Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci (2011) 2.33
Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci U S A (2003) 2.33
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation (2005) 2.23
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol (2007) 2.09
Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS One (2010) 2.03
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis (2008) 2.01
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging (2007) 1.99
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets (2009) 1.94
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol (2014) 1.83
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci (2008) 1.73
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience (2010) 1.70
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol (2001) 1.69
Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. Radiology (2014) 1.68
Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A (2002) 1.68
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol (2004) 1.66
Alzheimer disease. Dis Mon (2010) 1.64
Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest (2003) 1.59
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet (2014) 1.56
In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci U S A (2003) 1.52
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med (2008) 1.48
Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest (2005) 1.45
Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc Natl Acad Sci U S A (2006) 1.44
Immunotherapy for Alzheimer's disease. J Intern Med (2011) 1.43
Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics (2008) 1.42
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model. J Neurosci (2011) 1.41
Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not form plaques. Proc Natl Acad Sci U S A (2001) 1.41
Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 1.41
Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A (2011) 1.39
Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. Eur J Neurosci (2006) 1.38
Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol (2008) 1.38
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A (2009) 1.37
Protease-activated drug development. Theranostics (2012) 1.36
Search strategies used by APP transgenic mice during navigation in the Morris water maze. Learn Mem (2004) 1.35
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res (2009) 1.34
Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience (2006) 1.31
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Retracted Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration. J Neurosci (2011) 1.31
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis (2008) 1.29
The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J (2006) 1.29
A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord (2010) 1.29
Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J Biol Chem (2010) 1.28
Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol (2008) 1.27
Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci (2009) 1.27
Immunization delays the onset of prion disease in mice. Am J Pathol (2002) 1.26
G-CSF rescues the memory impairment of animal models of Alzheimer's disease. J Exp Med (2007) 1.24
Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem (2007) 1.22
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis (2008) 1.22
Transgenic models of Alzheimer's disease: learning from animals. NeuroRx (2005) 1.21
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets (2009) 1.20
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am J Pathol (2004) 1.20
Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest (2003) 1.19
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation (2010) 1.18
Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.17
Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Mol Ther (2008) 1.17
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol (2010) 1.16
Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an age-related selective uptake with reversal of learning impairment. Exp Neurol (2007) 1.16
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement (2009) 1.13
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.12
Bapineuzumab. Expert Opin Biol Ther (2010) 1.12
Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem (2013) 1.12
Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol (2004) 1.11
Imaging microglial activation during neuroinflammation and Alzheimer's disease. J Neuroimmune Pharmacol (2008) 1.11
Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric. Am J Pathol (2002) 1.11
Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med (2010) 1.09
Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol Lett (2007) 1.09
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09
Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J Neurosci Res (2009) 1.08
Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease. PLoS One (2009) 1.07
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
A cellular gene encodes scrapie PrP 27-30 protein. Cell (1985) 8.86
Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science (1995) 8.31
Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science (1987) 8.29
A growth chart for premature and other infants. Arch Dis Child (1971) 8.04
Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab (2001) 7.53
Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol (1997) 7.27
A cortical area selective for visual processing of the human body. Science (2001) 5.92
McrA and McrB restriction phenotypes of some E. coli strains and implications for gene cloning. Nucleic Acids Res (1988) 5.76
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature (1997) 5.47
Invitation to attend a health check in a general practice setting: comparison of attenders and non-attenders. J R Coll Gen Pract (1988) 5.27
Contextual cueing: implicit learning and memory of visual context guides spatial attention. Cogn Psychol (1998) 5.17
Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A (1998) 5.15
Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ (1994) 5.07
Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. Cell (1986) 4.82
Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell (1989) 4.73
Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome. Nature (1989) 4.69
Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res (1998) 4.68
Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature (2000) 4.68
Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature (1997) 4.59
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem (2001) 4.51
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 3.93
The cellular prion protein binds copper in vivo. Nature (1998) 3.92
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res (2000) 3.83
Randomised trial of personalised computer based information for cancer patients. BMJ (1999) 3.82
Linkage of prion protein and scrapie incubation time genes. Cell (1986) 3.69
Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J Biol Chem (1996) 3.63
TRAPP, a highly conserved novel complex on the cis-Golgi that mediates vesicle docking and fusion. EMBO J (1998) 3.49
Complete genomic sequence and analysis of the prion protein gene region from three mammalian species. Genome Res (1998) 3.44
Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med (1996) 3.23
Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res (1999) 3.08
The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J (1992) 3.04
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
Origin and molecular changes associated with emergence of a highly pathogenic H5N2 influenza virus in Mexico. Virology (1995) 2.99
Molecular determinants of amyloid deposition in Alzheimer's disease: conformational studies of synthetic beta-protein fragments. Biochemistry (1990) 2.93
Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. J Mol Biol (1999) 2.92
Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum (1998) 2.91
Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem (1999) 2.86
DNA microarrays of the complex human cytomegalovirus genome: profiling kinetic class with drug sensitivity of viral gene expression. J Virol (1999) 2.80
Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol (2000) 2.78
Structure of beta-crystallite assemblies formed by Alzheimer beta-amyloid protein analogues: analysis by x-ray diffraction. Biophys J (1993) 2.77
Transient symptomatic hypotension in patients on simvastatin. Lancet (1989) 2.67
A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A (1993) 2.63
alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem (2000) 2.60
Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A (1993) 2.58
Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci (1997) 2.55
Serum antibodies in epilepsy and seizure-associated disorders. Neurology (2005) 2.53
Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med (2002) 2.49
Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology (2012) 2.45
PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J (1998) 2.44
Molecular cloning of a human prion protein cDNA. DNA (1986) 2.43
Prion isolate specified allotypic interactions between the cellular and scrapie prion proteins in congenic and transgenic mice. Proc Natl Acad Sci U S A (1994) 2.38
Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res (1997) 2.34
Ypt1p implicated in v-SNARE activation. Nature (1994) 2.29
Anthropometric determination of leg fat and muscle plus bone volumes in young male and female adults. J Physiol (1969) 2.28
Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med (1995) 2.27
Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron (1999) 2.25
Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol Psychiatry (2013) 2.25
Histopathology of ischemic optic neuropathy. Am J Ophthalmol (1970) 2.24
Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia (2010) 2.21
Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem (1993) 2.18
Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J Neurosci (1996) 2.14
Genetics and polymorphism of the mouse prion gene complex: control of scrapie incubation time. Mol Cell Biol (1988) 2.14
Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol (1999) 2.14
Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy. Diabetes Educ (2002) 2.12
Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol (1999) 2.12
Economic burden of smoking in China, 2000. Tob Control (2006) 2.08
Altered glucose metabolism in microvessels from patients with Alzheimer's disease. Ann Neurol (1989) 2.08
A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis (2001) 2.07
Arm levitation in progressive supranuclear palsy. Neurology (1999) 2.06
Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science (1987) 2.06
Tissue donation: benefits, legal issues and the nurse's role. Nurs Stand (2006) 2.05
Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity (1997) 2.04
Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol (1999) 2.03
Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat Med (1999) 2.03
Proviral deletions and oncogene base-substitutions in insertionally mutagenized c-myc alleles may contribute to the progression of avian bursal tumors. Proc Natl Acad Sci U S A (1984) 2.02
Case report: a preterm infant with an extradural myxopapillary ependymoma component of a teratoma and high levels of alpha-fetoprotein. Pediatr Hematol Oncol (1999) 2.01
Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. J Biol Chem (1999) 2.00